This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing’s syndrome caused by a non-adrenal tumor.
Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.
Apply for this study at https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-02543